The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BackgroundSevere asthma is a high impact disease. Omalizumab targets the allergic inflammatory pathway; however, effectiveness data in a population with significant comorbidities are limited.
AimsTo describe severe allergic asthma, omalizumab treatment outcomes and predictors of response among the Australian Xolair Registry participants.
MethodsA web‐based post‐marketing surveillance registry was...
We evaluated the association between allergic conditions and the risk of glioma in case–control and cohort studies published so far on this issue. A total of 12 studies (10 case–control and 2 cohort studies) were included in the analysis, involving 61 090 participants, of whom 6408 had glioma. When compared with non‐allergic conditions, the pooled odds ratio (OR) with any allergic conditions for glioma...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.